Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H McCabe

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Journal of the American College of Cardiology|March 1, 1995
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson, C P Cannon, R N Piana, et al.
Circulation|April 20, 1999
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study GroupC M Gibson, S A Murphy, M J Rizzo, et al.
Journal of the American College of Cardiology|March 1, 1987
Incidence and management of limb ischemia with percutaneous wire-guided intraaortic balloon cathetersJ D Alderman, G I Gabliani, C H McCabe, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
Circulation|March 1, 1996
TIMI frame count: a quantitative method of assessing coronary artery flowC M Gibson, C P Cannon, W L Daley, et al.
Journal of the American College of Cardiology|April 1, 1994
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trialC P Cannon, C H McCabe, T D Henry, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 6, 2000
Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapyJ A de Lemos, E M Antman, D A Morrow, et al.
Circulation|October 12, 1999
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trialE M Antman, C H McCabe, E P Gurfinkel, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Journal of the American College of Cardiology|March 1, 1995
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson, C P Cannon, R N Piana, et al.
Circulation|April 20, 1999
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study GroupC M Gibson, S A Murphy, M J Rizzo, et al.
Journal of the American College of Cardiology|March 1, 1987
Incidence and management of limb ischemia with percutaneous wire-guided intraaortic balloon cathetersJ D Alderman, G I Gabliani, C H McCabe, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
Circulation|March 1, 1996
TIMI frame count: a quantitative method of assessing coronary artery flowC M Gibson, C P Cannon, W L Daley, et al.
Journal of the American College of Cardiology|April 1, 1994
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trialC P Cannon, C H McCabe, T D Henry, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 6, 2000
Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapyJ A de Lemos, E M Antman, D A Morrow, et al.
Circulation|October 12, 1999
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trialE M Antman, C H McCabe, E P Gurfinkel, et al.
Pageof 10